The daily burden for those living with type 1 diabetes is constant, and Breakthrough T1D remains focused on accelerating the path to cures for the disease,” said Nicholas Mamrak, Ph.D., scientist at ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...